G. COMMITMENTS AND CONTINGENCIES (Details Narrative) (USD $)	3 Months Ended		9 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Sep. 30, 2012
Research and development expense	$ 3,769,538	$ 2,469,166	$ 9,208,900	$ 7,519,586
Amortization of the deferred rent	161,866	174,773	489,902	528,498
Rent deposit included in non-current assets	1,670,917		1,670,917
R & D deferred rent liability	3,393		3,393		1,033
Deferred rent liability	13,759		13,759		15,479
Office equipment leased under a capital lease arrangement			During the nine months ended June 30, 2013, the Company leased office equipment under a capital lease arrangement. The term of the capital lease is 48 months and expires on September 30, 2016. The monthly lease payment is $1,025. The lease bears interest at approximately 16% per annum.
Collaborative Arrangements Erogmed
Research and development expense	$ 315,000		$ 315,000